1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

Clinical Breast Examination & Breast Self-Awareness

Evaluating breast health requires systematic clinical inspection and palpation, combined with patient education regarding normal breast anatomy.

Clinical Breast Examination (CBE) Technique

A standardized CBE begins with visual inspection in four sequential postural positions:

1. Arms resting relaxed at sides
2. Arms elevated directly overhead
3. Hands pressed firmly against iliac crests (contracting pectoralis major)
4. Torso leaning forward from waist

Inspect for asymmetries, contour changes, erythema, dimpling, nipple retraction, scaling, or peau d'orange (cutaneous lymphatic obstruction). Palpation is conducted supine with the ipsilateral arm behind the head. Using the pads of the middle three fingers, apply light, medium, and deep circular pressure in a vertical strip pattern—from clavicle to inframammary fold, and sternum to mid-axillary line, including the axillary tail of Spence. Bilateral axillary, infraclavicular, and supraclavicular lymph node basins must be palpated with the patient seated.

Breast Self-Awareness vs. Monthly Breast Self-Exam (BSE)

Major clinical guidelines have abandoned structured monthly breast self-examinations. Trials showed rigid monthly BSE did not decrease breast cancer mortality but doubled benign biopsies and heightened distress. Current consensus (ACOG, ACS) emphasizes breast self-awareness: educating women on their baseline breast appearance and texture, and encouraging prompt clinical evaluation if a new palpable mass, focal thickening, spontaneous nipple discharge, or skin retraction arises.

---

Screening Mammography Guidelines Across Organizations

Guidelines for average-risk women reflect growing evidence regarding breast cancer incidence in women in their 40s:

Screening vs. Diagnostic Mammography & Digital Breast Tomosynthesis (DBT)

• Screening Mammography: Standard two-view assessment per breast—craniocaudal (CC) and mediolateral oblique (MLO)—performed on asymptomatic women.
• Diagnostic Mammography: Indicated to evaluate abnormal screening exams or clinical signs (palpable lump, focal pain, skin retraction, spontaneous discharge). Incorporates spot compression, magnification views, and on-site radiologist interpretation.
• Digital Breast Tomosynthesis (3D Mammography / DBT): Captures multiple low-dose X-ray projections across an arc to reconstruct thin 1 mm slices. DBT reduces false-positive recall rates by ~15% and increases invasive cancer detection by 30%–40%, particularly in heterogeneously or extremely dense breasts (BI-RADS breast density categories C and D).

---

High-Risk Stratification & Supplemental Breast MRI

Risk Assessment Models

1. Gail Model (BCRAT): Estimates 5-year and lifetime risk based on age, age at menarche, age at first live birth, first-degree relatives with breast cancer, and prior benign breast biopsies (especially atypical hyperplasia). High risk is defined as a 5-year risk ≥1.67% or lifetime risk ≥20%. Limitations: Omits paternal family history, second-degree relatives, and age of diagnosis in relatives.
2. Tyrer-Cuzick (IBIS) Model: Incorporates comprehensive multigenerational maternal and paternal pedigrees, bilateral breast cancers, ovarian cancer, age of onset, dense breasts, Ashkenazi Jewish heritage, and exogenous hormones. Highly sensitive for hereditary risk.

Criteria for Supplemental Screening Breast MRI

Annual contrast-enhanced breast MRI (typically alternating every 6 months with screening mammography, beginning at age 25–30) is recommended for:

• Lifetime breast cancer risk ≥ 20% to 25% based on pedigree models (e.g., Tyrer-Cuzick)
• Known pathogenic BRCA1 or BRCA2 mutation (or TP53, PTEN, CDH1, STK11)
• Untested first-degree relative of a known BRCA mutation carrier
• History of mantle or chest radiation therapy between ages 10 and 30 (screening starts 8–10 years post-radiation or at age 25, whichever is later)

---

Diagnostic Imaging Modalities & BI-RADS Classification

Modality selection depends on patient age and clinical presentation:

• Age < 30 Years: Targeted breast ultrasound is the primary first-line modality. Young women possess dense fibroductal tissue that impairs mammographic sensitivity, and their tissue is more radiosensitive. Mammography is added only if ultrasound demonstrates suspicious features.
• Age ≥ 30 Years: Diagnostic mammography PLUS targeted ultrasound is the standard initial imaging workup for a palpable breast mass.
• Pregnancy / Lactation: Targeted ultrasound is first-line; mammography with abdominal shielding is safe if malignancy is suspected.

BI-RADS Categories & Clinical Management Directives

---

Clinical Triage of Palpable Breast Masses & Nipple Discharge

Differential Diagnosis of Palpable Masses

1. Fibroadenoma: Most common benign solid tumor in women aged 15–35. Characteristics: well-circumscribed, mobile, nontender, rubbery mass, usually 1–3 cm. Hormone-responsive (may enlarge during pregnancy or luteal phase).
2. Breast Cyst: Fluid-filled round cavity common in perimenopausal women (ages 35–50). Characteristics: smooth, fluctuant, tender, acute onset, fluctuating with menses. Aspiration confirms diagnosis if symptomatic; clear fluid without residual mass requires no further workup.
3. Malignancy (Invasive Carcinoma / DCIS): Hard, fixed, nontender mass with irregular borders, often accompanied by skin dimpling, nipple retraction, or hard, matted axillary lymphadenopathy.

Evaluation and Triage of Nipple Discharge

• Physiologic Discharge: Bilateral, multiductal, non-spontaneous (expressible only on manipulation); milky, clear, yellow, green, or brown; guaiac-negative. Causes: pregnancy, lactation, hypothyroidism (TRH stimulates prolactin), prolactinoma, medications (antipsychotics, SSRIs, metoclopramide, verapamil). Diagnostic workup: serum hCG, prolactin, TSH, and medication audit.
• Pathologic Discharge: Spontaneous, unilateral, uniductal (emerges from a single duct orifice); bloody, serosanguineous, or watery; or associated with a palpable mass or age ≥40. Causes: Intraductal papilloma (>50% of cases; benign lactiferous duct polyp), duct ectasia, ductal carcinoma in situ (DCIS; 10%–15%), or invasive ductal carcinoma. Diagnostic workup: Diagnostic mammography with subareolar and targeted ultrasound, followed by surgical referral for terminal duct excision (microdochectomy).

Fibrocystic Change, Mastalgia & Breast Surgery History

• Fibrocystic change: Cyclic, bilateral tenderness and lumpy nodularity, worst in the upper outer quadrants during the late luteal phase. Nonproliferative changes do not raise cancer risk; atypical ductal or lobular hyperplasia raises lifetime risk about four-fold and should prompt high-risk counseling.
• Mastalgia: Cyclic pain is hormonal and usually bilateral; noncyclic focal pain deserves diagnostic imaging of the painful area. First-line care is a well-fitted support bra, reassurance, and topical NSAIDs such as diclofenac gel. Danazol (the only FDA-approved agent, androgenic) and tamoxifen are reserved for severe refractory pain.
• Breast augmentation: Implants do not change screening age; mammography adds implant-displacement (Eklund) views. For silicone implants, FDA labeling advises ultrasound or MRI to look for silent rupture 5–6 years after placement and every 2–3 years thereafter. A new, late seroma or swelling a year or more after a textured implant suggests breast implant–associated anaplastic large cell lymphoma (BIA-ALCL): obtain ultrasound-guided aspiration with CD30 immunohistochemistry.
• Reduction mammoplasty: May reduce milk supply; postoperative fat necrosis and scarring can mimic a mass on exam or imaging, so compare with prior studies.